Robert Ordonez, MD
Family Medicine · Lubbock, TXNPI 1740375880
Payments from drug & device makers
Across 647 payments — averaging $29.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- AbbVie$2K
- Amgen$1K
- Lilly USA, LLC$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$781
- AstraZeneca$444
- plus $6K from 45 others
What the payments were for
- Consulting fees$5,26427%
- Travel & lodging$1,2677%
- Food & beverage$12,59765%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$6,677
- VRAYLAR$250
- QULIPTA$224
- REZDIFFRA$139
- DEXCOM G7 GSS (161)$130
- DEXCOM STELO GLUCOSE BIOSENSOR$130
- CAPLYTA$129
- FREESTYLE LIBRE 3$124
- Repatha$123
- ZEPBOUND$123
- AIMOVIG$114
- Kerendia$114
- Ozempic$103
- EVENITY$103
- UBRELVY$101
- Tymlos$101
- INJECTAFER$100
- XIFAXAN$100
How this compares
$19,247 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 76 | $89,351 |
| OzempicSemaglutide | 88 | $88,943 |
| Repatha SureclickEvolocumab | 82 | $67,079 |
| EliquisApixaban | 87 | $64,148 |
| JardianceEmpagliflozin | 56 | $43,996 |
| MyrbetriqMirabegron | 57 | $34,191 |
| KerendiaFinerenone | 32 | $29,072 |
| AptiomEslicarbazepine Acetate | 23 | $28,692 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $25,234 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,531 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $21,667 |
| TrulicityDulaglutide | 17 | $19,919 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $19,495 |
| XareltoRivaroxaban | 18 | $18,009 |
| TrintellixVortioxetine Hydrobromide | 23 | $15,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,195 | $109,26993 claims |
| Novo NordiskOzempic | $222 | $88,94388 claims |
| PfizerEliquis, Premarin | $342 | $68,37998 claims |
| Boehringer IngelheimJardiance | $149 | $43,99656 claims |
| Astellas Pharma US IncMyrbetriq | $170 | $34,19157 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $150 | $33,88856 claims |
| BayerKerendia | $313 | $29,07232 claims |
| Johnson & JohnsonXarelto | $220 | $18,00918 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $203 | $15,42823 claims |
| Redhill Biopharma Inc.Movantik | $30 | $9,51921 claims |
| AstraZenecaSymbicort | $444 | $6,04226 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $371 | $5,76621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lubbock
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.